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Abstract
Genetic variations, such as single nucleotide polymorphisms (SNPs) in microRNAs (miRNA) or in the miRNA binding sites
may affect the miRNA dependent gene expression regulation, which has been implicated in various cancers, including
breast cancer, and may alter individual susceptibility to cancer. We investigated associations between miRNA related SNPs
and breast cancer risk. First we evaluated 2,196 SNPs in a case-control study combining nine genome wide association
studies (GWAS). Second, we further investigated 42 SNPs with suggestive evidence for association using 41,785 cases and
41,880 controls from 41 studies included in the Breast Cancer Association Consortium (BCAC). Combining the GWAS and
BCAC data within a meta-analysis, we estimated main effects on breast cancer risk as well as risks for estrogen receptor (ER)
and age defined subgroups. Five miRNA binding site SNPs associated significantly with breast cancer risk: rs1045494 (odds
ratio (OR) 0.92; 95% confidence interval (CI): 0.88–0.96), rs1052532 (OR 0.97; 95% CI: 0.95–0.99), rs10719 (OR 0.97; 95% CI:
0.94–0.99), rs4687554 (OR 0.97; 95% CI: 0.95–0.99, and rs3134615 (OR 1.03; 95% CI: 1.01–1.05) located in the 39 UTR of CASP8,
HDDC3, DROSHA, MUSTN1, and MYCL1, respectively. DROSHA belongs to miRNA machinery genes and has a central role in
initial miRNA processing. The remaining genes are involved in different molecular functions, including apoptosis and gene
expression regulation. Further studies are warranted to elucidate whether the miRNA binding site SNPs are the causative
variants for the observed risk effects.
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Introduction
Breast cancer is the most common women’s cancer and is a
leading cause of cancer mortality [1]. Inherited genetic variation
has been associated with the initiation, development and
progression of breast cancer. Studies on twins have suggested that
hereditary predisposing factors are involved in up to one third of
all breast cancers [2]. Many genetic loci have been associated with
breast cancer risk and collectively explain approximately 35% of
the familial risk [3,4]. The largest genetic association study of
breast cancer to date identified 41 novel low penetrance
susceptibility loci [4] by selecting nearly 30,000 SNPs from a
meta-analysis of nine genome-wide association (GWA) studies and
genotyping them using 41,785 cases and 41,880 controls of
European ancestry from studies in the Breast Cancer Association
Consortium (BCAC). These 41 susceptibility loci probably
represent the tip of the ice berg, and additional SNPs from the
combined GWAS might explain a similar fraction of familial risk
to that attributed to the already identified loci [4].
Mature miRNAs are 20–23 nucleotide, single-stranded RNA
molecules that play a crucial role in gene expression regulation for
many cellular processes including differentiation potential and
development pattern. MiRNAs undergo a stepwise maturation
process involving an array of miRNA machinery components.
Drosha and DGCR8 mediate the cleavage of long primary
miRNA transcripts (pri-miRNAs) into shorter pre-miRNAs in the
nucleus [5,6]. The pre-miRNAs are then transported to the
cytoplasm where they are further cleaved by Dicer to produce
mature miRNAs [7]. MiRNAs interact by pairing with the 39
untranslated region (UTR), and also within the coding region and
59 UTR of the corresponding mRNAs leading to mRNA
destabilization, cleavage or translation repression. More effective
mRNA destabilization is achieved when miRNA targets the
3’UTR rather than other mRNA regions [8–10]. An individual
miRNA may regulate approximately 100 distinct mRNAs, and
together more than 1000 human miRNAs are believed to
modulate more than half of the mRNA species encoded in the
genome [11,12]. Additionally, most mRNAs possess binding sites
for miRNAs [13]. MiRNAs are involved in tumorigenesis in that
they can be either oncogenic when tumor suppressor genes are
targeted, or genomic guardians (tumour suppressor miRNAs)
when oncogenes are targeted [14]. Additionally it has been
suggested that they may modulate both metastasis [15] and
chemotherapy resistance [16]. MiRNAs have also been shown to
have altered expression levels in tumours compared to normal
tissue and between tumor subtypes in breast cancer among other
carcinoma types [17–19]. SNPs may affect miRNA machinery
genes or miRNAs activity; however SNPs can also create, abolish
or modify miRNA binding sites in their binding regions.
Polymorphisms in miRNA binding sites have been studied in
regard to the risk of several cancers [20], including breast cancer
[21–23]. These studies have found evidence for association of
miRNA related SNPs and cancer risk, but the study sample sizes
have been relatively small.
In this study, we investigate associations between miRNA-
related polymorphisms and breast cancer risk by using a meta-
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using 41,785 cases and 41,880 controls of European ancestry from
the BCAC. To our knowledge, this is thus far the largest
investigation of associations between miRNA-related polymor-
phisms and breast cancer susceptibility.
Materials and Methods
SNP selection and genotyping
SNPs in mature or pre-miRNAs, in genes of the miRNA
machinery and in 3’UTR regions of protein coding genes with a
potential effect on miRNA binding were systematically searched
from Ensembl (hg18/build36) and Patrocles databases [24].
Additionally, tagging SNPs for such with r
2$0.8 were also
identified utilizing the public HapMap SNP database. By this in
silico approach we identified altogether 147,801 candidate SNPs
and 12,550 tagging SNPs. These SNPs were then overlayed with
those from the combined GWAS from the BCAC [4] and
altogether 2196 SNPs were present (either genotyped or imputed)
in the combined GWAS. These SNPs were genotyped with
Illumina or Affymetrix arrays, as described previously [25–32].
The combined GWAS data were imputed for all scans using
HapMap version 2 CEU as a reference in similar fashion to that
presented by Michailidou and colleagues [4] with the exception
that the HapMap version 2 release 21 was used at the time the
overlay was performed. Analysis using a 1-degree-of-freedom
trend test of these 2196 SNPs in the combined GWAS indicated
some evidence of association with breast cancer risk for 44 SNPs
(p,0.09). Notably, the combined GWAS included imputed data
generated using HapMap version 2 release 21 (based on NCBI
build 35 (dbSNP b125)), whereas the results presented here for the
combined GWAS are based on imputation using HapMap version
2 release 22 (based on NCBI build 36 (dbSNP b126)). In the
release 22, a number of SNPs were excluded due to mapping
inconsistencies in build 35 relative to build 36. Hence, the
estimates from the combined GWAS may slightly differ from the
initial association analysis. The 44 SNPs (including 30 candidate
and 14 tagging SNP) were genotyped on additional samples in the
BCAC using the custom Illumina Infinium array (iCOGS) which
included a total of 211,155 SNPs as described previously. The
detailed description of quality control process for combined
GWAS and iCOGS genotyping data was presented in [4].
Of the 42 SNPs that passed quality control [4], two were
located in miRNA genes (one candidate SNP located in pre-
miRNA hsa-miR-2110 and one tag SNP tagging a mature hsa-
mir-548l variant), and four SNPs were located in miRNA
machinery genes (SMAD5, SND1, CNOT4 and DROSHA).
The genotyped DROSHA SNP tags the 39 UTR miRNA binding
site variant in the DROSHA gene. The remaining 38 candidate or
tag SNPs were located in, or tagged to a predicted miRNA binding
site in the 39 UTR of protein coding genes. All 42 SNPs are
described in Table 1. The workflow of the SNP selection in
different stages is illustrated in Figure 1.
Study sample
The combined GWAS included nine breast cancer studies
totalling 10,052 cases and 12,575 controls of European ethnic
background. Details and study-specific subject numbers are
presented in Table S1. Since the GWAS were limited to patients
of European ethnic background we further utilized 41,785 cases
ascertained for their first primary, invasive breast cancer and
41,880 controls of European ancestry from 41 BCAC studies
genotyped using the iCOGS array (Table S2). For a subgroup
analysis of ER negative and ER positive cases, as well as cases aged
less than 50 years at diagnosis, we included all the cases for which
the respective data were available. The ER subgroup analysis was
based on 702 ER negative cases and 2,019 ER positive cases from
five GWAS studies and 7,200 ER negative cases from 40 BCAC
studies and 26,302 ER positive cases from 34 BCAC studies. The
analysis of cases aged less than 50 years at diagnosis was based on
3,470 cases from three GWAS studies and 9,483 cases from
35 BCAC studies. All participating studies conform to the
Declaration of Helsinki and were approved by the respective
ethical review boards and ethics committees (Tables S1 and S2),
and all participants in these studies had provided written consent
for the research.
Statistical methods
We used logistic regression to estimate per-allele log-odds ratios
and standard errors including the study as a covariate. We also
included principal components as covariates in order to correct for
potential hidden population structure. In the GWAS, for two
studies (UK2 and HEBCS) the estimates were adjusted for the first
three principal components and in the iCOGS analysis we used
the first six principal components and an additional component to
reduce inflation for the LMBC study, as described previously [4].
Subgroup analyses were carried out for ER negative and positive
subgroups and for the group aged less than 50 years at diagnosis.
For meta-analysis, we combined the estimates from the combined
GWAS and iCOGS with a fixed effects model using the inverse
variance weighted method. In the meta-analysis, the subjects
involved in both combined GWAS and iCOGS (1880) were only
taken into account once. In order to adust for P-values against
multiple testing, we used Benjamini Hochberg correction. The
adjusted P-values are shown in Table 2 along with the nominal P-
values. In the text we report the nominal P-values. The statistical
analyses were conducted using the R 2.14.0 statistical computing
environment (http://www.r-project.org/).
Results
For the 42 SNPs we successfully genotyped, estimates of
association from the combined GWAS and from iCOGS analysis
are shown in Table S3. Twenty-one SNPs showed consistent
Figure 1. Workflow of miRNA SNP selection.
doi:10.1371/journal.pone.0109973.g001
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MicroRNA Related Polymorphisms and Breast Cancer Riskassociations with breast cancer risk in the combined GWAS and in
iCOGS analysis; results from the meta-analysis are shown in
Table 2. The most significantly associated SNP, rs702681 (OR
1.06 [95%CI 1.04–1.08]; P 3.9610
210), is located in the 3’UTR
of MIER3, close to the known breast cancer susceptibility gene
MAP3K1. The SNP rs702681 is located at the same 5q11.2 locus
as the previously published risk SNP rs889312 [33] (correlation
r
2=0.3). When the two SNPs were analysed in the same logistic
regression model, the association with rs889312, but not that with
rs702681 remained nominally statistically significant, suggesting
that rs702681 is unlikely to be the causal SNP at this locus. The
five SNPs with the significant novel associations from the meta-
analysis (P#5.07610
23and adjusted P#3.55610
22 after correc-
tion for multiple testing) were rs1045494, (OR 0.92 [95%CI 0.88–
0.96]; P= 5.90610
25), rs1052532, (OR 0.97 [95%CI 0.95–0.99];
P=7.78610
24), rs10719, (OR 0.97 [95%CI 0.94–0.99];
P=1.35610
23) rs4687554 (OR 0.97 [95%CI 0.95–0.99];
P=1.71610
23) and rs3134615 (OR 1.03 [95%CI 1.01–1.05];
P=5.07610
23) located in 39 UTR of Caspase-8 (CASP8), HD
Domain Containing 3 (HDDC3), DROSHA, Musculoskeletal,
Embryonic Nuclear Protein 1 (MUSTN1) and V-Myc Myelocy-
tomatosis Viral Oncogene Homolog 1 (MYCL1), respectively
(Table 2). SNP rs1045494 is tagging the hsa-miR-938 binding site
SNP rs1045487 (r
2=1.0) of CASP8 and the SNP rs1052532 in
HDDC3 is predicted to abolish the binding site for hsa-miR-1224-
3p. The SNP rs10719 is predicted to abolish the hsa-miR-1298
binding site in the 39 UTR of DROSHA. SNP rs4687554 tags the
hsa-miR-891b binding site SNP rs6445538 (r
2=1.0) of MUSTN1
and rs3134615 is located at the binding site of hsa-miR-1827 of
MYCL1. There was no evidence for heterogeneity in the per-allele
OR for any SNP. The per study per allele ORs for these five
miRNA binding site SNPs from the combined GWAS along with
per-SNP heterogeneity variance P-values are shown in Figure S1
and from the iCOGS in Figure S2. Next we analysed the SNPs by
ER status-defined subtype, and for cases aged less than 50 years at
diagnosis, for risk associations in the meta-analysis of combined
GWAS and iCOGS (Tables S4, S5 and S6). These analyses did
not reveal any additional significant results. For rs1045494 in
CASP8, rs4687554 in MUSTN1 and rs3134615 in MYCL1 (OR
1.03 [95%CI 1.01–1.05]; P=7.75610
24) a more significant
association with breast cancer risk was found for the ER positive
subgroup than in the main analysis, but the result from the test for
heterogeneity by ER status was not significant (data not shown).
All associations were estimated using an additive inheritance
model. Dominant and recessive models did not improve the
estimates (data not shown).
Discussion
We investigated associations between genetic variation in
miRNAs, in the genes of the miRNA machinery and in the
miRNA binding sites and the risk of breast cancer. We identified
several SNPs that are predicted to abolish an miRNA binding site
and that are significantly associated with breast cancer risk.
Previous studies investigating miRNA related SNPs, especially in
miRNA binding sites have included predefined sets of genes.
Nicoloso and colleagues investigated 38 previously identified
breast cancer risk SNPs and found two to modify miRNA binding
sites in TGFB1 and XRCC1 in vitro [23]. Neither of these were
included in our data set. Liang and colleagues investigated 134
potential miRNA binding sites in cancer-related genes and found
six miRNA binding site SNPs that were associated with ovarian
cancer risk [34].
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MicroRNA Related Polymorphisms and Breast Cancer RiskIn the meta-analysis of combined GWAS and iCOGS for main
effects, for four of the five most significant miRNA binding site
SNPs, the minor allele was associated with a decreased breast
cancer risk. The minor allele of SNP rs3134615 in 39 UTR of
MYCL1 was associated with an increased breast cancer risk. All
the five most significant miRNA binding site SNPs locate in 39
UTR and have been predicted to abolish the miRNA binding site.
The defect in miRNA-mediated regulation would be expected to
lead to an increase in the translation of the corresponding encoded
protein. The five genes, whose regulation may be affected by the
miRNA-associated SNPs, include the pre-apoptotic gene CASP8,
HDDC3, miRNA biogenesis master regulator DROSHA, MYC-
family member MYCL1 and MUSTN1. CASP8 is involved in
apoptosis in breast cancer cells [35], and many studies have
reported polymorphisms in this gene to be associated with risks for
several cancers [36,37] including breast cancer [38,39], indicating
the importance of CASP8 in tumor development. SNP rs1045494
studied here is located close to the coding region SNP rs1045485
that has been previously shown to have a stronger protective effect
[38,40,41]. Interestingly, Michalidou and colleagues reported this
SNP as having only weak evidence for an association (P 0.0013 in
combined GWAS and iCOGS) [4], but these two SNPs
(rs1045485 and rs1045494) are not correlated (r
2=0.001 in
Caucasian population). Neither is rs1045494 correlated with the
more strongly associated rs1830298 SNP, identified through fine-
mapping of the region (r
2=0.02) [42]. Rs1045494 tags SNP
rs1045487 (r
2=1.0) which is predicted to abolish the hsa-miR-938
binding site and thus may affect CASP8 expression. There is very
little reported evidence on the involvement of HDDC3 or the hsa-
miR-1224-3p in cancer, indicating a novel association with risk.
HDDC3 has been suggested to be involved in the starvation
response [43]. The HDDC3 gene is expressed at higher levels by
several different tumor types, including breast tumors, than by
normal tissue [44]. DROSHA is a miRNA master regulator. It is a
member of the RNase III enzyme family, belongs to the miRNA
biogenesis pathway and is the core nuclease that processes pri-
miRNAs into pre-miRNAs in the nucleus [5,6]. The SNP rs10719
in the 39 UTR of DROSHA is predicted to abolish the hsa-miR-
1298 binding site. Hsa-miR-1298 is predicted to target DROSHA
by the Patrocles prediction as well as by TargetScan [45] and
PITA [46] prediction algorithms. Recently a small Korean study
reported another SNP rs644236, tagging the SNP rs10719
(r
2=0.955 in CEU population and r
2=0.876 in Asian population
(combined CHB and JPT)) to be associated with elevated breast
cancer risk [47]. When taking into account the opposite major and
minors alleles in the Asian and European populations for SNPs
rs644236 and rs10719, this result is in concordance with our
results where both the combined GWAS as well as the iCOGS
analysis consistently indicated an association of the minor allele of
SNP rs10719 with reduced breast cancer risk. We also found the
minor allele of SNP rs3134615 in the 39 UTR of MYCL1 to be
associated with an increased risk. MYCL1 (L-MYC) belongs to the
same family of transcription factors as the known proto-oncogene
MYC (C-MYC) and they share a high degree of structural
similarity [48]. The MYCL1 gene has previously been reported to
be amplified and overexpressed in ovarian cancer [49]. A case-
control study by Xiong and colleagues reported SNP rs3134615 to
be significantly associated with increased risk of small cell lung
cancer [50]. SNP rs3134615 was predicted by Patrocles to abolish
the hsa-miR-1827 binding site. This has also been suggested by
functional studies where MYCL1 was found as the target of hsa-
miR-1827 and the SNP rs3134615 was also found to increase
MYCL1 expression [50]. The evidence from functional studies is
consistent with our finding that SNP rs3134615 might increase
breast cancer risk. MUSTN1 has been shown to be involved in the
development and regeneration of the musculoskeletal system [51].
Thus far no evidence of association between MUSTN1 and breast
cancer has been reported, but the MUSTN1 gene is expressed in
the mammary glands [52].
Since only a small fraction of miRNA binding sites has been
experimentally validated, we selected SNPs that had been
computationally predicted to affect miRNA binding sites. For
our original SNP selection we used the Patrocles database that
contains predicted miRNA binding sites and also compiles
perturbation prediction of SNP effects. There are a multitude of
prediction programs and their performance has been evaluated
[53]. Witkos and colleagues find target prediction algorithms that
utilize orthologous sequence alignment, like Patrocles, to be the
most reliable.
The followup of the 42 miRNA related SNPs identified five
significant associations with breast cancer risk. Although the
individual risk effects were subtle, considering that we could only
investigate a small proportion of our initial in silico data set of
miRNA related SNPs (over 140,000 SNPs) this may suggest that
genetic polymorphisms affecting the miRNA regulation could
have a considerable combined effect on breast cancer risk.
It should be noted that, until fine mapping studies are carried
out for these loci, it is not clear whether these miRNA-related
SNPs are the variants responsible for the observed associations.
This comprehensive analysis of miRNA related polymorphisms
using a large two stage study of women with European ancestry
provides evidence for miRNA related SNPs being potential
modulators of breast cancer risk.
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